Necrotizing Fasciitis Market Size, Share & Trends Analysis Report By Type, By Treatment (Immunotherapies, Antitoxin Adjunct For Invasive GAS, Empiric Broad-spectrum Antibacterials), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online P
Description
Necrotizing Fasciitis Market Summary
The global necrotizing fasciitis market size was estimated at USD 1,027.24 million in 2024 and is projected to reach USD 2,097.81 million by 2033, growing at a CAGR of 8.3% from 2025 to 2033. The market is experiencing growth due to several key factors. Increasing awareness about the severity and rapid progression of the disease has led to a higher demand for effective treatments.
Advances in medical technology and the availability of innovative antibiotics and surgical interventions improve patient outcomes, further driving market expansion. Necrotizing Fasciitis (NF) is a serious skin and soft tissue infection that spreads along fascial planes with limited blood supply. It often leaves overlying tissues initially unaffected and delays diagnosis and treatment. As it progresses, it can involve fascia, peri-fascial planes, surrounding skin, soft tissue, and muscle. The condition affects around 0.4 per 100,000 people in the U.S. annually, with some areas reporting up to 1 per 100,000.
In addition,the rising prevalence of risk factors such as diabetes, obesity, and immunocompromised conditions is contributing to a greater number of cases. According to the International Diabetes Federation, diabetes was responsible for 3.4 million deaths in 2024, equivalent to one death every nine seconds, and 589 million adults (aged 20-79 years) are living with the condition worldwide. This rising diabetic population significantly increases the susceptibility to Necrotizing Fasciitis, fueling the demand for specialized care. Moreover, the growing focus of healthcare providers on early diagnosis and treatment, along with increased healthcare spending, is supporting the market's steady growth.
Global Necrotizing Fasciitis Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global necrotizing fasciitis market report based on type, treatment, distribution channel, and region:
The global necrotizing fasciitis market size was estimated at USD 1,027.24 million in 2024 and is projected to reach USD 2,097.81 million by 2033, growing at a CAGR of 8.3% from 2025 to 2033. The market is experiencing growth due to several key factors. Increasing awareness about the severity and rapid progression of the disease has led to a higher demand for effective treatments.
Advances in medical technology and the availability of innovative antibiotics and surgical interventions improve patient outcomes, further driving market expansion. Necrotizing Fasciitis (NF) is a serious skin and soft tissue infection that spreads along fascial planes with limited blood supply. It often leaves overlying tissues initially unaffected and delays diagnosis and treatment. As it progresses, it can involve fascia, peri-fascial planes, surrounding skin, soft tissue, and muscle. The condition affects around 0.4 per 100,000 people in the U.S. annually, with some areas reporting up to 1 per 100,000.
In addition,the rising prevalence of risk factors such as diabetes, obesity, and immunocompromised conditions is contributing to a greater number of cases. According to the International Diabetes Federation, diabetes was responsible for 3.4 million deaths in 2024, equivalent to one death every nine seconds, and 589 million adults (aged 20-79 years) are living with the condition worldwide. This rising diabetic population significantly increases the susceptibility to Necrotizing Fasciitis, fueling the demand for specialized care. Moreover, the growing focus of healthcare providers on early diagnosis and treatment, along with increased healthcare spending, is supporting the market's steady growth.
Global Necrotizing Fasciitis Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global necrotizing fasciitis market report based on type, treatment, distribution channel, and region:
- Type Outlook (Revenue, USD Million, 2021 - 2033)
- Type I (Polymicrobial)
- Type II (Monomicrobial)
- Type III (Gas gangrene / clostridial myonecrosis)
- Treatment Outlook (Revenue, USD Million, 2021 - 2033)
- Empiric broad-spectrum antibacterials
- MRSA-coverage add-ons
- Antitoxin adjunct for invasive GAS
- Pathogen-targeted antibacterial regimens
- Antifungals for necrotizing fungal infections
- Immunotherapies
- Distribution ChannelOutlook (Revenue, USD Million, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- MEA
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
100 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Type
- 1.2.2. Treatment
- 1.2.3. Distribution Channel
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR’s Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
- Chapter 3. Necrotizing Fasciitis Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter’s Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis
- Chapter 4. Necrotizing Fasciitis Market: Type Business Analysis
- 4.1. Type Market Share, 2024 & 2033
- 4.2. Type Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 - 2033 (USD Million)
- 4.4. Type I (Polymicrobial)
- 4.4.1. Type I (Polymicrobial) market estimates & forecasts, 2021 - 2033 (USD Million)
- 4.5. Type II (Monomicrobial)
- 4.5.1. Type II (Monomicrobial) market estimates & forecasts, 2021 - 2033 (USD Million)
- 4.6. Type III (Gas gangrene / clostridial myonecrosis)
- 4.6.1. Type III (Gas gangrene / clostridial myonecrosis) market estimates & forecasts, 2021 - 2033 (USD Million)
- Chapter 5. Necrotizing Fasciitis Market: Treatment Business Analysis
- 5.1. Treatment Market Share, 2024 & 2033
- 5.2. Treatment Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2021 to 2033 (USD Million)
- 5.4. Empiric broad-spectrum antibacterials
- 5.4.1. Empiric broad-spectrum antibacterials market estimates & forecasts, 2021 - 2033 (USD Million)
- 5.5. MRSA-coverage add-ons
- 5.5.1. MRSA-coverage add-ons market estimates & forecasts, 2021 - 2033 (USD Million)
- 5.6. Antitoxin adjunct for invasive GAS
- 5.6.1. Antitoxin adjunct for invasive GAS market estimates & forecasts, 2021 - 2033 (USD Million)
- 5.7. Pathogen-targeted antibacterial regimens
- 5.7.1. Pathogen-targeted antibacterial regimens market estimates & forecasts, 2021 - 2033 (USD Million)
- 5.8. Antifungals for necrotizing fungal infections
- 5.8.1. Antifungals for necrotizing fungal infections market estimates & forecasts, 2021 - 2033 (USD Million)
- 5.9. Immunotherapies
- 5.9.1. Immunotherapies market estimates & forecasts, 2021 - 2033 (USD Million)
- Chapter 6. Necrotizing Fasciitis Market: Distribution Channel Business Analysis
- 6.1. Distribution Channel Market Share, 2024 & 2033
- 6.2. Distribution Channel Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
- 6.4. Hospital Pharmacies
- 6.4.1. Hospital pharmacies market estimates & forecasts, 2021 - 2033 (USD Million)
- 6.5. Retail Pharmacies
- 6.5.1. Retail pharmacies market estimates & forecasts, 2021 - 2033 (USD Million)
- 6.6. Online pharmacies
- 6.6.1. Online pharmacies market estimates & forecasts, 2021 - 2033 (USD Million)
- Chapter 7. Necrotizing Fasciitis Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Share Analysis, 2024 & 2033
- 7.2. Regional Market Dashboard
- 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
- 7.4. North America
- 7.4.1. North America necrotizing fasciitis market estimates & forecasts, by country, 2021 - 2033 (USD Million)
- 7.4.2. U.S.
- 7.4.2.1. Key country dynamics
- 7.4.2.2. Type disease prevalence
- 7.4.2.3. Regulatory framework
- 7.4.2.4. Reimbursement framework
- 7.4.2.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.4.3. Canada
- 7.4.3.1. Key country dynamics
- 7.4.3.2. Type disease prevalence
- 7.4.3.3. Regulatory framework
- 7.4.3.4. Reimbursement framework
- 7.4.3.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.4.4. Mexico
- 7.4.4.1. Key country dynamics
- 7.4.4.2. Type disease prevalence
- 7.4.4.3. Regulatory framework
- 7.4.4.4. Reimbursement framework
- 7.4.4.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.5. Europe
- 7.5.1. Europe necrotizing fasciitis market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.5.2. UK
- 7.5.2.1. Key country dynamics
- 7.5.2.2. Type disease prevalence
- 7.5.2.3. Regulatory framework
- 7.5.2.4. Reimbursement framework
- 7.5.2.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.5.3. Germany
- 7.5.3.1. Key country dynamics
- 7.5.3.2. Type disease prevalence
- 7.5.3.3. Regulatory framework
- 7.5.3.4. Reimbursement framework
- 7.5.3.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.5.4. France
- 7.5.4.1. Key country dynamics
- 7.5.4.2. Type disease prevalence
- 7.5.4.3. Regulatory framework
- 7.5.4.4. Reimbursement framework
- 7.5.4.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.5.5. Italy
- 7.5.5.1. Key country dynamics
- 7.5.5.2. Type disease prevalence
- 7.5.5.3. Regulatory framework
- 7.5.5.4. Reimbursement framework
- 7.5.5.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.5.6. Spain
- 7.5.6.1. Key country dynamics
- 7.5.6.2. Type disease prevalence
- 7.5.6.3. Regulatory framework
- 7.5.6.4. Reimbursement framework
- 7.5.6.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.5.7. Denmark
- 7.5.7.1. Key country dynamics
- 7.5.7.2. Type disease prevalence
- 7.5.7.3. Regulatory framework
- 7.5.7.4. Reimbursement framework
- 7.5.7.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.5.8. Sweden
- 7.5.8.1. Key country dynamics
- 7.5.8.2. Type disease prevalence
- 7.5.8.3. Regulatory framework
- 7.5.8.4. Reimbursement framework
- 7.5.8.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.5.9. Norway
- 7.5.9.1. Key country dynamics
- 7.5.9.2. Type disease prevalence
- 7.5.9.3. Regulatory framework
- 7.5.9.4. Reimbursement framework
- 7.5.9.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.6. Asia Pacific
- 7.6.1. Asia Pacific necrotizing fasciitis market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.6.2. China
- 7.6.2.1. Key country dynamics
- 7.6.2.2. Type disease prevalence
- 7.6.2.3. Regulatory framework
- 7.6.2.4. Reimbursement framework
- 7.6.2.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.6.3. Japan
- 7.6.3.1. Key country dynamics
- 7.6.3.2. Type disease prevalence
- 7.6.3.3. Regulatory framework
- 7.6.3.4. Reimbursement framework
- 7.6.3.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.6.4. India
- 7.6.4.1. Key country dynamics
- 7.6.4.2. Type disease prevalence
- 7.6.4.3. Regulatory framework
- 7.6.4.4. Reimbursement framework
- 7.6.4.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.6.5. Australia
- 7.6.5.1. Key country dynamics
- 7.6.5.2. Type disease prevalence
- 7.6.5.3. Regulatory framework
- 7.6.5.4. Reimbursement framework
- 7.6.5.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.6.6. South Korea
- 7.6.6.1. Key country dynamics
- 7.6.6.2. Type disease prevalence
- 7.6.6.3. Regulatory framework
- 7.6.6.4. Reimbursement framework
- 7.6.6.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.6.7. Thailand
- 7.6.7.1. Key country dynamics
- 7.6.7.2. Type disease prevalence
- 7.6.7.3. Regulatory framework
- 7.6.7.4. Reimbursement framework
- 7.6.7.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.7. Latin America
- 7.7.1. Latin America necrotizing fasciitis market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.7.2. Brazil
- 7.7.2.1. Key country dynamics
- 7.7.2.2. Type disease prevalence
- 7.7.2.3. Regulatory framework
- 7.7.2.4. Reimbursement framework
- 7.7.2.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.7.3. Argentina
- 7.7.3.1. Key country dynamics
- 7.7.3.2. Type disease prevalence
- 7.7.3.3. Regulatory framework
- 7.7.3.4. Reimbursement framework
- 7.7.3.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.8. Middle East and Africa
- 7.8.1. Middle East and Africa necrotizing fasciitis market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.8.2. South Africa
- 7.8.2.1. Key country dynamics
- 7.8.2.2. Type disease prevalence
- 7.8.2.3. Regulatory framework
- 7.8.2.4. Reimbursement framework
- 7.8.2.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.8.3. Saudi Arabia
- 7.8.3.1. Key country dynamics
- 7.8.3.2. Type disease prevalence
- 7.8.3.3. Regulatory framework
- 7.8.3.4. Reimbursement framework
- 7.8.3.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.8.4. UAE
- 7.8.4.1. Key country dynamics
- 7.8.4.2. Type disease prevalence
- 7.8.4.3. Regulatory framework
- 7.8.4.4. Reimbursement framework
- 7.8.4.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- 7.8.5. Kuwait
- 7.8.5.1. Key country dynamics
- 7.8.5.2. Type disease prevalence
- 7.8.5.3. Regulatory framework
- 7.8.5.4. Reimbursement framework
- 7.8.5.5. Market estimates & forecasts, 2021 - 2033 (USD Million)
- Chapter 8. Competitive Landscape
- 8.1. Participant Overview
- 8.2. Company Market Position Analysis
- 8.3. Company Categorization
- 8.4. Strategy Mapping
- 8.5. Company Profiles/Listing
- 8.5.1. Pfizer Inc.
- 8.5.1.1. Overview
- 8.5.1.2. Financial Performance
- 8.5.1.3. Product Benchmarking
- 8.5.1.4. Strategic Initiatives
- 8.5.2. Merck & Co., Inc. (MSD)
- 8.5.2.1. Overview
- 8.5.2.2. Financial Performance
- 8.5.2.3. Product Benchmarking
- 8.5.2.4. Strategic Initiatives
- 8.5.3. Gilead Sciences
- 8.5.3.1. Overview
- 8.5.3.2. Financial Performance
- 8.5.3.3. Product Benchmarking
- 8.5.3.4. Strategic Initiatives
- 8.5.4. Astellas Pharma
- 8.5.4.1. Overview
- 8.5.4.2. Financial Performance
- 8.5.4.3. Product Benchmarking
- 8.5.4.4. Strategic Initiatives
- 8.5.5. Basilea Pharmaceutica
- 8.5.5.1. Overview
- 8.5.5.2. Financial Performance
- 8.5.5.3. Product Benchmarking
- 8.5.5.4. Strategic Initiatives
- 8.5.6. CSL Behring
- 8.5.6.1. Overview
- 8.5.6.2. Financial Performance
- 8.5.6.3. Product Benchmarking
- 8.5.6.4. Strategic Initiatives
- 8.5.7. Takeda
- 8.5.7.1. Overview
- 8.5.7.2. Financial Performance
- 8.5.7.3. Product Benchmarking
- 8.5.7.4. Strategic Initiatives
- 8.5.8. Grifols
- 8.5.8.1. Overview
- 8.5.8.2. Financial Performance
- 8.5.8.3. Product Benchmarking
- 8.5.8.4. Strategic Initiatives
- 8.5.9. Octapharma
- 8.5.9.1. Overview
- 8.5.9.2. Financial Performance
- 8.5.9.3. Product Benchmarking
- 8.5.9.4. Strategic Initiatives
- 8.5.10. Hikma Pharmaceuticals
- 8.5.10.1. Overview
- 8.5.10.2. Financial Performance
- 8.5.10.3. Product Benchmarking
- 8.5.10.4. Strategic Initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
